Loading…
Korean biotech developing antibody-drug-conjugate (ADC) cancer therapies, spun out of Samsung Medical Center research.
Korean biotech developing antibody-drug-conjugate (ADC) cancer therapies, spun out of Samsung Medical Center research.
Cannot sell a drug yet, so income comes from licence fees: up-front and milestone payments from large drug companies that take rights to its technology, with royalties if a drug reaches the market. ADCs link an antibody that homes in on cancer cells to a toxic payload.
Moat: narrow (IP / patents). Proprietary ADC linker/payload technology validated by a large Boehringer Ingelheim licensing deal.
Headquarters: Seoul, South Korea · Founded: 2018
Size Aimed Bio (0009K0.KS) is a South Korea Industrials company (Miscellaneous Commercial Services) with a market value of $875M, the 252nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩18,250 on 6 Nov 2026.
Performance Over six months the shares fell 61.0%, against -2.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 222.6% over the last twelve months (peer median +3.3%); the operating margin is 36.3% (peer median 10.2%).
Valuation It trades at 16.4× enterprise value to sales against a peer median of 3.9× (most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +652%, so the hurdle is -639 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.3 points above its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩66.8B | ₩47.3B | ₩11.8B | ₩171M | ₩111M |
| Revenue growth | — | +302% | +6,769% | +54% | — |
| Gross profit | n/a | ₩38.7B | ₩6.35B | -₩4.36B | -₩4.56B |
| EBITDA | ₩25.5B | ₩22.2B | ₩1.06B | -₩5.36B | -₩4.81B |
| Net income | ₩38.6B | ₩5.02B | -₩3.30B | -₩9.02B | -₩6.17B |
| Free cash flow | ₩9.61B | ₩17.5B | -₩5.10B | -₩3.44B | -₩4.36B |
| Capital expenditure | ₩1.19B | ₩363M | ₩1.68B | ₩796M | ₩521M |
| Total debt | ₩1.57B | ₩1.16B | ₩41.9B | ₩11.8B | ₩1.01B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Aimed Bio 0009K0.KS | $875M | -61% | +223% | 36% | 16.4× | 13.2% |
| ABL Bio 298380.KS | $1.49B | -73% | -64% | -251% | 55.7× | n/a |
| LigaChem Biosciences 141080.KS | $1.59B | -68% | -33% | -208% | 18.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0009K0.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.5% | +0.1% | 3rd lowest of 21 |
| 6-month return | -61.0% | -2.3% | lowest of 21 |
| Distance from 52-week high | -77.2% | -33.9% | lowest of 21 |
| Revenue growth (TTM) | +222.6% | +3.3% | highest of 21 |
| Operating margin | 36.3% | 10.2% | 3rd highest of 21 |
| EV / Sales | 16.4× | 3.9× | most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 13.2% | 4.1% | 5th most demanding of 16 |
| Growth delivered (Del g) | +652.2% | +14.5% | highest of 16 |
| Hurdle (Req g minus delivered) | -639.0 pp | -12.3 pp | least demanding of 16 |
| ROIC minus cost of capital | +10.3 pp | +2.7 pp | 4th highest of 20 |
| EV / EBITDA | 43.1× | 7.9× | most expensive of 11 |
| Net debt / EBITDA | -3.6× | 0.6× | 2nd least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aimed Bio 0009K0.KS | South Korea | $875M | -61% | +223% | 36% | 16.4× | 13.2% | +652.2% |
| IP Group plc IPO.L | United Kingdom | $879M | +13% | -37% | 51% | 15.4× | n/a | n/a |
| Xi'an High Voltage Apparatus Research Institute 688334.SS | China | $889M | -10% | +4% | 29% | 4.7× | -2.4% | +20.3% |
| Zhejiang Meorient Commerce & Exhibition 300795.SZ | China | $890M | -1% | -3% | 18% | 8.2× | n/a | n/a |
| DOOSAN TESNA 131970.KS | South Korea | $861M | -53% | +3% | 11% | 3.9× | 17.8% | +18.1% |
| NOMURA 9716.T | Japan | $861M | +4% | -10% | 7% | 0.6× | -8.4% | +8.6% |
| Funshine Culture 300860.SZ | China | $858M | +21% | -49% | -35% | 14.0× | 27.8% | -24.6% |
| Embedway Technologies (Shanghai) 603496.SS | China | $910M | -37% | +4% | 1% | 6.2× | 54.3% | +14.5% |
| TaskUs TASK | United States | $833M | +41% | +11% | 12% | 1.0× | 0.5% | +19.9% |
| Anbang Save-Guard 603373.SS | China | $830M | +30% | -1% | 14% | 2.0× | 6.7% | +5.6% |
| Karnov KAR.ST | Sweden | $828M | +16% | -4% | 20% | 3.9× | 4.1% | +27.9% |
| Shaanxi Fenghuo Electronics 000561.SZ | China | $929M | -24% | +8% | -26% | 4.4× | n/a | n/a |
| Wavestone WAVE.PA | France | $931M | -22% | +1% | 12% | 0.8× | -5.3% | +18.0% |
| PharmaResources (Shanghai) 301230.SZ | China | $822M | -4% | +9% | 0% | 7.4× | 42.7% | +19.5% |
| W.A.G. Payment Solutions EWG.L | United Kingdom | $935M | -4% | +16% | 3% | 0.4× | -1.7% | +12.2% |
| Cuscal CCL.AX | Australia | $815M | +26% | +19% | 12% | n/a | n/a | n/a |
| Beyondsoft 002649.SZ | China | $813M | -12% | -6% | 2% | 0.6× | 8.3% | +9.2% |
| Service Stream SSM.AX | Australia | $943M | +7% | +1% | 3% | 0.6× | 11.7% | +24.0% |
| B2 Impact B2I.OL | Norway | $947M | +1% | +9% | 48% | 5.0× | -8.3% | +3.1% |
| Omat Advanced Materials (Guangdong) 688530.SS | China | $809M | -16% | +82% | 9% | 6.1× | n/a | n/a |
| transcosmos 9715.T | Japan | $802M | -12% | +6% | 4% | 0.2× | -18.5% | +3.2% |